featured
Carboplatin-Based Doublet Plus Bevacizumab Beyond Progression vs Carboplatin-Based Doublet Alone in Platinum-Sensitive Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Carboplatin-Based Doublet Plus Bevacizumab Beyond Progression Versus Carboplatin-Based Doublet Alone in Patients With Platinum-Sensitive Ovarian Cancer: A Randomised, Phase 3 Trial
Lancet Oncol 2021 Feb 01;22(2)267-276, S Pignata, D Lorusso, F Joly, C Gallo, N Colombo, C Sessa, A Bamias, V Salutari, F Selle, S Frezzini, U De Giorgi, P Pautier, A Bologna, M Orditura, C Dubot, A Gadducci, S Mammoliti, I Ray-Coquard, E Zafarana, E Breda, L Favier, A Ardizzoia, S Cinieri, R Largillier, D Sambataro, E Guardiola, R Lauria, C Pisano, F Raspagliesi, G Scambia, G Daniele, F PerroneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.